BioVex Group, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BioVex Group, Inc.
With valuations down and borrowing costs up, many industry insiders are expecting Darwinian scenes in biotech this year. Survival of the fittest is the order of the day: companies with riskier, less commercially defined propositions will struggle, while platform companies with multiple shots on strong goals will increasingly find favor in a more risk-averse environment.
In this month’s Digital Health Roundup, Medtech Insight’s Reed Miller offers a recap from the recent TCT 2022 meeting and talks about Butterfly Network’s expansion into Africa while Marion Webb highlights her interview with Aidoc’s CEO Elad Walach discussing plans for the AI-based software company.
The company received a $5m grant from the Bill & Melinda Gates Foundation to improve access to medical imaging across Sub-Saharan Africa.
The development of oncolytic virus therapy has gained momentum over the past decade, due to its relatively safe mode of action and potential to enhance existing treatment options. A third of cancer vaccines in development are now oncolytic viruses, which are being developed for about 40 different types of cancer. In Vivo takes a closer look at therapies in development to see what the future holds for this promising therapy.
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.